Abstract
In deceased donors, Ischemia/Reperfusion Injury (IRI) is an important cause of allograft dysfunction. Prolonged cold and warm ischemia time leads to a high risk of early post-transplant complications, including acute and chronic rejection. Ischemia not only up-regulates inflammatory cytokines and chemokines, but also enhances the expression of MHC-class II and adhesion molecules on epithelial and dendritic cells. Moreover, the Danger Associated Molecular Patterns (DAMPs) released from stressed or dying cells, not only cause or amplify tissue inflammation and trigger tissue repair in response to IRI, but also act as adjuvants that enhance DC maturation and potentiate the adaptive immune response. In this review, we will also discuss about whether donor or recipient DCs are more important in the process of ischemia enhanced acute rejection.
Keywords: Dendritic cells, Kidney transplantation, Allograft rejection, Ischemia/reperfusion injury, APC, CTLs.
Current Gene Therapy
Title:How Do Dendritic Cells Play the Role in Ischemia/Reperfusion Triggered Kidney Allograft Rejection
Volume: 17 Issue: 6
Author(s): Songjie Cai*, Naotsugu Ichimaru and Shiro Takahara*
Affiliation:
- Department of Advanced Technology for Transplantation, Osaka University Graduate School of Medicine, Osaka,Japan
- Department of Advanced Technology for Transplantation, Osaka University Graduate School of Medicine, Osaka,Japan
Keywords: Dendritic cells, Kidney transplantation, Allograft rejection, Ischemia/reperfusion injury, APC, CTLs.
Abstract: In deceased donors, Ischemia/Reperfusion Injury (IRI) is an important cause of allograft dysfunction. Prolonged cold and warm ischemia time leads to a high risk of early post-transplant complications, including acute and chronic rejection. Ischemia not only up-regulates inflammatory cytokines and chemokines, but also enhances the expression of MHC-class II and adhesion molecules on epithelial and dendritic cells. Moreover, the Danger Associated Molecular Patterns (DAMPs) released from stressed or dying cells, not only cause or amplify tissue inflammation and trigger tissue repair in response to IRI, but also act as adjuvants that enhance DC maturation and potentiate the adaptive immune response. In this review, we will also discuss about whether donor or recipient DCs are more important in the process of ischemia enhanced acute rejection.
Export Options
About this article
Cite this article as:
Cai Songjie *, Ichimaru Naotsugu and Takahara Shiro *, How Do Dendritic Cells Play the Role in Ischemia/Reperfusion Triggered Kidney Allograft Rejection, Current Gene Therapy 2017; 17 (6) . https://dx.doi.org/10.2174/1566523218666180214095956
DOI https://dx.doi.org/10.2174/1566523218666180214095956 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Supplementation of Creatine and Ribose Prevents Apoptosis and Right Ventricle Hypertrophy in Hypoxic Hearts
Current Pharmaceutical Design Histone Methylation and Transcriptional Regulation in Cardiovascular Disease
Cardiovascular & Hematological Disorders-Drug Targets Inhibitors of the Microsomal Prostaglandin E2 Synthase-1 as Alternative to Non Steroidal Anti-Inflammatory Drugs (NSAIDs) – A Critical Review
Current Medicinal Chemistry Potential Use of Nanomedicine for Drug Delivery Across the Blood-Brain Barrier in Healthy and Diseased Brain
CNS & Neurological Disorders - Drug Targets HSP27 Protects the Blood-Brain Barrier Against Ischemia-Induced Loss of Integrity
CNS & Neurological Disorders - Drug Targets Mitochondria as a Target for Exercise-Induced Cardioprotection
Current Drug Targets STAT-1 and STAT-3: Closely Related Transcription Factors with Antagonistic Effects on Cell Proliferation and Apoptosis
Current Genomics pNitro-Tyr-PseAAC: Predict Nitrotyrosine Sites in Proteins by Incorporating Five Features into Chou’s General PseAAC
Current Pharmaceutical Design Soluble Epoxide Hydrolase Inhibitors and their Potential for Treatment of Multiple Pathologic Conditions
Current Medicinal Chemistry Novel Thiourea Derivatives Bearing Sulfonamide Moiety as Anticancer Agents Through COX-2 Inhibition
Anti-Cancer Agents in Medicinal Chemistry The Role of Thiols in Liver Ischemia-Reperfusion Injury
Current Pharmaceutical Design Regulation of Adrenomedullin and its Family Peptide by RAMP System – Lessons from Genetically Engineered Mice
Current Protein & Peptide Science Application of Carbon Nanotubes In Drug Delivery of Non-cancerous Diseases: A Review
Current Pharmaceutical Design Non-Cardiomyocytes in Heart Regeneration
Current Drug Targets Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction
Current Pharmaceutical Design Genetics in Anti-Platelet Treatment
Current Pharmaceutical Design NGAL is a Precocious Marker of Therapeutic Response
Current Pharmaceutical Design Inhibition of Matrix Metalloproteinases (MMPs) as a Potential Strategy to Ameliorate Hypertension-Induced Cardiovascular Alterations
Current Drug Targets From Polypharmacology to Target Specificity: The Case of PARP Inhibitors
Current Topics in Medicinal Chemistry Lost in Translation: What is Limiting Cardiomyoplasty and Can Tissue Engineering Help?
Current Stem Cell Research & Therapy